TruAlt Bioenergy H1 FY27 Revenue Surges 243% to ₹1,438 Crore; PAT at ₹94 Crore
TruAlt Bioenergy reported H1 FY27 revenue of ₹1,437.98 crore, a 243% increase YoY. EBITDA grew 532% to ₹233.92 crore, and PAT was ₹94.27 crore. Q2 FY27 revenue was ₹811.10 crore. The company is advancing CBG projects and a proposed 100 million litres per annum SAF facility, which received a ₹150 crore grant.
The significant increase in financial metrics, coupled with strategic growth initiatives like the SAF facility and expansion in CBG projects, are material developments that are likely to have a high impact on investor perception and the company's future outlook.
The company reported substantial year-on-year growth in revenue, EBITDA, and PAT, indicating a strong financial performance. Strategic diversification initiatives and positive operational updates further contribute to a positive sentiment.
TruAlt Bioenergy Limited announced its Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2026. The company reported a significant increase in revenue and profitability for H1 FY27. Revenue from operations surged by 243% year-on-year to ₹1,437.98 crore, compared to ₹418.75 crore in the same period last year. EBITDA saw a substantial rise of 532% to ₹233.92 crore from ₹36.99 crore, and the profit after tax (PAT) reached ₹94.27 crore, a notable improvement from a loss of ₹33.27 crore in H1 FY26.
For the second quarter (Q2 FY27) ended September 30, 2026, revenue from operations stood at ₹811.10 crore, with EBITDA at ₹101.16 crore and PAT at ₹34.99 crore. The company's investment in a 1,300 KLPD dual-feed ethanol platform, which now covers 65% of its total installed capacity of 2,000 KLPD, has strengthened its operating flexibility. This dual-feed capability allows processing of both sugar-based and grain-based feedstocks, enabling longer operating cycles and improved asset utilization.
Commenting on the performance, Vijay Nirani, Managing Director, TruAlt Bioenergy Limited, highlighted the benefits of the dual-feed integration in navigating seasonal feedstock constraints and extending production cycles. He emphasized the company's focus on strengthening procurement efficiency and cost management to ensure resilient operating performance and sustainable profitability. The company is also advancing its diversification strategy through Compressed Biogas (CBG) partnerships with Sumitomo Corporation and GAIL (India) Limited, and a proposed 100 million litres per annum Sustainable Aviation Fuel (SAF) facility.
The company's strategic outlook includes expanding its CBG operations and developing the SAF facility in Srikakulam, Andhra Pradesh, for which it has secured a ₹150 crore grant under the PM JI-VAN Yojana. TruAlt's fuel retail network is also expanding, with seven outlets operational and four under construction. The company is focused on strengthening its core operations, executing projects with discipline, and deploying capital responsibly to deliver long-term value.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.